HeyJaredOncology Spotlight
Interviews with those who are working on the war against cancer. Brought to you by the ONCOassist team.
- Indexed episodes, last 90 days
- 2
- Latest publication
- Sep 17, 2026
- Audience
- Checking…
- Earliest in this view
- Sep 4, 2026
Latest episodes
Oncology News: Trastuzumab deruxtecan EU Approval, Sevabertinib & Major Phase III Cancer Data (opens the original)
Read excerpt
🎥 Latest Oncology News Four developments across breast cancer, lung cancer, multiple myeloma and prostate cancer. In this episode of Oncology Updates from ONCOassist , Dr. Stephanie Haddad reviews: 🔹 HER2+ metastatic breast cancer: The European Commission has approved Enhertu (Trastuzumab deruxtecan) plus Pertuzumab as first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer. In Phase III DESTINY-Breast09, the combination reduced the risk of disease progression
Oncology News: mRNA Cancer Vaccine Milestone & New Pancreatic Cancer Approval (opens the original)
Read excerpt
🎥 Latest Oncology News From a landmark mRNA-based individualized neoantigen therapy result in melanoma to an important advance in metastatic pancreatic cancer, this edition brings several major developments across oncology. Dr. Stephanie Haddad , Hematology/Oncology Fellow and Academic Chief Fellow at UT Health San Antonio/Mays Cancer Center, breaks down four updates oncology professionals should know. The FDA approved Daraxonrasib , a RAS inhibitor, for metastatic pancreatic adenocarcinoma foll
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Not enough subject data for this period yet.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.